Navigation Links
Addition of INTEGRILIN(R) (Eptifibatide) to Bivalirudin Plus Standard of Care Inhibits Platelet Aggregation in Patients Undergoing Elective Coronary Stenting
Date:11/5/2007

to demonstrate the inhibitory effect of INTEGRILIN(R) on the physical characteristics of a platelet-fibrin clot.

CLEAR PLATELETS 2 builds on the results of the original CLEAR PLATELETS study, which demonstrated that adding INTEGRILIN(R) to a 300-mg loading dose of clopidogrel produced greater platelet inhibition and reduced cardiac biomarkers than clopidogrel alone in patients undergoing elective stenting. Data from this study were presented at the 2004 American Heart Association Scientific Sessions. CLEAR PLATELETS 2 was an investigator-initiated study funded by Schering-Plough.

About Sinai Hospital of Baltimore

Sinai Hospital of Baltimore is a member of LifeBridge Health, a regional health organization, which includes Northwest Hospital Center, Levindale Hebrew Geriatric Center and Hospital, Jewish Convalescent & Nursing Home and related subsidiaries and affiliates.

About INTEGRILIN(R) Injection

INTEGRILIN(R) is indicated for the treatment of patients with acute coronary syndrome (unstable angina/non-ST-segment-elevation myocardial infarction), including patients who are to be managed medically and those undergoing percutaneous coronary intervention (PCI). It is also indicated in the United States for the treatment of patients at time of PCI, including in patients undergoing intracoronary stenting.

INTEGRILIN(R) is contraindicated in patients with a history of bleeding diathesis, or evidence of abnormal bleeding within the previous 30 days; severe hypertension (systolic blood pressure greater than 200 mm Hg or diastolic blood pressure greater than 110 mm Hg) not adequately controlled on antihypertensive therapy; major surgery within the preceding six weeks; history of stroke within 30 days, or any history of hemorrhagic stroke; current or planned administration of another parenteral GP IIb-IIIa inhibitor; dependency on renal dialysis; or known hypersensitivity to any component of the product.

Bleeding is the most common co
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
2. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
3. First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival
4. PTC Therapeutics Announces Additional Results from Phase 2 Study of PTC124 in Duchenne Muscular Dystrophy
5. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
6. Coley Pharmaceutical Group and Pfizer Nominate Additional Anti-Cancer Compound for Clinical Development
7. Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
8. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
9. Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors
10. Semafores PI3 Kinase Inhibitor SF1126 is Active Against Tumor and Tumor Cells and Synergizes with Standard Chemotherapy Agents
11. Cleveland Clinic Researchers Identify Mechanism Behind Platelet Function and Potentially Fatal Blood Clot Formation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2008)...tatistical significance , , ISELIN, N.J., N...ion (Nasdaq: PARS ) today announced results from...ulsion (NE) drug delivery technology formulated wi...lti-center, randomized, double-blinded, placebo-co...f the Company,s 3% Diclofenac Diethanolamine NanoE...
(Date:11/18/2008)...stCall/ -- NeuroDiscovery Ltd (ASX:,NDL), a speci...pment Company,and Sosei Group Corporation ("Sose...onal biopharmaceutical company, today announce tha...e-clinical efficacy data for NSL-043/SD118.,This ...uropathic pain and has,successfully completed Pha...
(Date:11/18/2008)...diagnosed, elderly AML patients , , PRINCET...uticals today announced that the first patient has...dy of CPX-351 (Cytarabine:Daunorubicin) Liposome I...eloid leukemia (AML). , , The first patient...dical College of Cornell University and New York ...
(Date:11/12/2008)...D. Watson, Marilyn & James Simons and,Sherry Lansi...ov. 12 J. Craig Venter,...er Institute (JCVI), was,awarded the Double Helix ...,November 6th at a gala event in New York City., ...ith Dr. James D.,Watson for making each of their i...
Breaking Medicine Technology:Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream 2Sosei and NeuroSolutions Present Further Data on NSL-043/SD118 at the Society for Neuroscience 38th Annual Meeting 2Sosei and NeuroSolutions Present Further Data on NSL-043/SD118 at the Society for Neuroscience 38th Annual Meeting 3Celator(R) Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study with CPX-351 2Celator(R) Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study with CPX-351 3J. Craig Venter, Ph.D. Receives Double Helix Medal from Cold Spring Harbor Laboratory 2Pulmo BioTech Announces Appointment of Chief Financial Officer 5069 1Pulmo BioTech Announces Appointment of Chief Financial Officer 5069 2Pulmo BioTech Announces Appointment of Chief Financial Officer 5069 3Got Fat 3F 3A Plastic Surgeons Review Fat Melting and Fat Grafting Procedures 1960 1Got Fat 3F 3A Plastic Surgeons Review Fat Melting and Fat Grafting Procedures 1960 2Got Fat 3F 3A Plastic Surgeons Review Fat Melting and Fat Grafting Procedures 1960 3Environmental fate of nanoparticles depends on properties of water carrying them 3161 1Environmental fate of nanoparticles depends on properties of water carrying them 3161 2Environmental fate of nanoparticles depends on properties of water carrying them 3161 3Thermage a Leading Aesthetic Medical Device Company Announces First Time Exhibitor Status at ACOG Meeting 18263 1Thermage a Leading Aesthetic Medical Device Company Announces First Time Exhibitor Status at ACOG Meeting 18263 2Thermage a Leading Aesthetic Medical Device Company Announces First Time Exhibitor Status at ACOG Meeting 18263 3
(Date:11/21/2008)...nd schools need to work together to stop abusive b... (HealthDay News) -- Behavior that was once dismis...ying. , And as mounting research shows the nega...tal-health professionals, schools, parents and eve...ombat this threatening behavior. , "Bullying s...
(Date:11/21/2008)...1, 2008)The University of Texas Health Science Cen... Excellence in Aging Studies (TEXAS), to promote g...gious $2 million award from the Donald W. Reynolds... "This will allow us to teach geriatric medicine p... student to practicing physicians. With the reach ...
(Date:11/21/2008)...Nov. 21 The Providence S...ced that Craig A. Norris, the Company,s,Chief Ope...s Board of,Directors. Mr. Norris, appointment fi...n of Steven I. Geringer and returns the board to s...mittee of the Board. , Mr. Norris, age 41, ...
(Date:11/21/2008)...anzel proved effective against Lennox-Gastaut synd...) -- A new drug called Banzel (rufinamide) has bee...re form of epilepsy called Lennox-Gastaut syndrome...Friday. , The approval was based on results of ... ages 4 to 30. Compared to patients who took a pla...
Breaking Medicine News(10 mins):Health News:Getting Tough on Bullying 2Health News:Getting Tough on Bullying 3Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 2Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 3Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 4Health News:Craig A. Norris Appointed to Providence Service Corporation Board of Directors 2Health News:Craig A. Norris Appointed to Providence Service Corporation Board of Directors 3Health News:FDA Approves New Drug for Severe Epilepsy 2
...has been tons of information circulating around do...ign has asked donor-conceived parents to speak to ...ities were flooded with inquiries in this regard. ...lls and emails from parents of donor-conceived chi...
...bad-based Dishman Pharmaceuticals and Chemicals Lt...rvices business of US-based Solutia Inc for 74.5 m...ement for purchasing 100 per cent stake in CarboGe... pharmaceutical services division, Dishman said in...
...ng a decrease in the child mortality rate from 86 ...lans to bring it down further by earmarking Rs 2.6...ildren. // The benefits reaching women and childr... to all and the government will spend Rs 2.63 cror...
...sing serious concern over growing problems due to ...Social Justice and Empowerment Meira Kumar today s...tems in the region to check it. There is a need to...ng and reporting systems for all seven-sister stat...
Other Medicine News:
...The ACCU-Beam® line of Surgical Microscope Acc...litters, objective lenses, fiber optic cables, and...e Dual Adaptor allows the surgeon to document proc...eo or 35mm photography. Many different types of ad...
...The ACCU-Beam® line of Surgical Microscope Acc...litters, objective lenses, fiber optic cables, and...ersal Microsurgical Video Adaptor (US pat. no. 5,2...both single-chip and 3CCD cameras on the same adap...
...ALLEGRO Topolyzer and T-CAT have been optimized to...rection and to interact in perfect synchronization...ll necessary treatment and patient parameters are ...GRETTO WAVE laser systems via diskette, mini CD or...
...The WaveScan WaveFront System is an ophthalmic dia...ror and wavefront aberrations of the human eye usi...ents can be used to determine regular (sphero-cyli...rrations) that cause decreased or blurry vision in...
Medicine Products: